Premium
Why therapeutic drug monitoring is needed for monoclonal antibodies and how do we implement this?
Author(s) -
Mould DR
Publication year - 2016
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.278
Subject(s) - monoclonal antibody , medicine , therapeutic drug monitoring , drug , disease , disease monitoring , therapeutic approach , pharmacology , intensive care medicine , immunology , antibody
Monoclonal antibodies (mAbs) have improved clinical outcomes for many therapeutic indications. However, extensive between‐subject variability (BSV) contributes to therapeutic failures through suboptimal exposure. Therapeutic drug monitoring (TDM) is routinely implemented for inflammatory diseases; improving outcomes and reducing treatment costs. BSV can be more extensive with anticancer mAbs. Clearance BSV is associated with patient factors and disease burden, suggesting that TDM could benefit anticancer mAbs, as was seen with inflammatory disease, however, there are many hurdles.